Detomidine is an imidazole derivative and α₂-adrenergic receptor agonist, used as a large animal sedative, primarily used in horses. It is usually available as the salt detomidine hydrochloride. It is a prescription medication available to veterinarians s + some more technical info. Pharmacologically, detomidine produces dose dependent sedation, spinal and supraspinal analgesia and muscle relaxation by activating central and peripheral α₂ receptors, with characteristic cardiovascular effects including bradycardia, reduced cardiac output and an initial peripheral vasoconstriction. Formulations are supplied as aqueous solutions for IV or IM administration, are standardized for potency and sterility, and are routinely monitored by HPLC or LC-MS based assays. Detomidine is metabolized hepatically and cleared primarily in urine, and its effects are reversible with α₂ antagonists such as atipamezole; handling, storage and prescribing are controlled under veterinary regulations.
Parent: Detomidine / Medetomidine
Commercial detomidine hydrochloride products are controlled to pharmaceutical impurity limits and monitored by validated analytical methods. Typical internal specifications used by manufacturers specify total related substances at or below approximately 0.5 to 1.5 percent w/w depending on monograph and regulatory region, with any single unidentified impurity usually limited to 0.1 to 0.5 percent. Common related compounds monitored include detomidine free base or partially neutralized forms, N-oxide oxidation products, demethylated or dealkylated analogs, positional isomers and residual synthetic precursors; residual solvents and inorganic salt content are also assessed. Identification and quantification are typically performed by HPLC with UV or mass spectrometric detection, with complementary confirmation by NMR when needed, and specifications are set to ensure safety, potency and stability throughout labeled shelf life.
Detomidine is used by veterinarians to sedate, restrain and provide analgesia in large animals, most commonly horses, for clinical procedures, examinations and as a premedication for general anesthesia.
Both are α₂-adrenergic agonists but detomidine is generally more potent and longer acting with higher α₂ selectivity, producing more pronounced and longer lasting sedation in horses; xylazine has a shorter duration and is commonly used across a wider range of species. Cardiovascular and respiratory side effect profiles are similar in type but differ in magnitude and duration.
A well known veterinary brand name for detomidine is Dormosedan; detomidine products are also marketed under other regional veterinary trade names and generic formulations.
Common side effects include bradycardia, reduced cardiac output, changes in blood pressure with initial hypertension followed by hypotension, decreased respiratory rate, reduced gastrointestinal motility, ataxia and sweating; severe reactions can include pronounced cardiovascular depression and the drug should be used under veterinary supervision with reversal agents available.
